This is certainly a good development but still many hurdles and years to go before approval of this antibiotic. I wouldn't hold my breath a huge return through royalties as the medical profession will be subscribing any new antibiotics as little as possible to avoid creating the same issues we currently have again. The main prize, in $ return, for shareholders will be the billion $ reward I think. Few more years to go and hopefully that reward will still be in place.
Accelerated Approval for RECCE® 327, page-41
-
- There are more pages in this discussion • 54 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RCE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
46.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $118.1M | |||
| Open | High | Low | Value | Volume |
| 46.5¢ | 46.5¢ | 46.5¢ | $2.131K | 4.582K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1263 | 46.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 46.5¢ | 11173 | 5 |
View Market Depth
| Last trade - 12.38pm 04/12/2024 (20 minute delay) ? |
| RCE (ASX) Chart |
